BiotechTube
Cellular Logistics

Cellular Logistics

Madison, United States· Est.
cellogistics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $5M

Overview

Cellular Logistics is a private, preclinical-stage biotech founded in 2017 and based in Madison, Wisconsin. The company has developed CFX™, a first-of-its-kind iPSC-derived biomaterial designed as a therapeutic and delivery matrix for cardiac repair. Its strategy targets both acute myocardial infarction to prevent heart failure and chronic heart failure to restore function, positioning it in the large and underserved cardiovascular regenerative medicine market. The company holds key patents and has recently secured funding for assay development.

Cardiovascular

Technology Platform

CFX™, an iPSC-derived therapeutic biomaterial designed to modulate cardiac wound healing and serve as a supportive matrix for stem cell delivery to enable heart tissue remuscularization.

Funding History

2
Total raised:$5M
Seed$2.5M
Seed$2.5M

Opportunities

The company targets the massive, growing, and underserved global heart failure market with a potential disease-modifying therapy.
Success could lead to a blockbuster product for both acute intervention and chronic treatment.
The iPSC-derived platform may offer manufacturing and scalability advantages over other cell-based approaches.

Risk Factors

The field of cardiac regeneration has seen many clinical failures; proving robust efficacy is a major hurdle.
As a preclinical, private company, it faces significant financing risks to reach clinical trials.
Regulatory pathway for a novel iPSC-derived biomaterial, potentially as a combination product, is complex and untested.

Competitive Landscape

Cellular Logistics competes in the cardiac regenerative medicine space, which includes companies developing direct cell therapies (e.g., mesenchymal stem cells, cardiosphere-derived cells), gene therapies, and other biomaterials/scaffolds. Its key differentiator is the use of an iPSC-derived biomaterial designed to actively modulate the cardiac microenvironment and enhance cell-based repair, addressing historical challenges of poor cell retention and survival.

More companies in Cell & Gene Therapy →More companies in United States →